# BridgeBio Pharma, Inc.: Form SCHEDULE 13D/A, filed Aug 17, 2026

- Company: [BridgeBio Pharma, Inc.](/companies/bbio.md) (CIK 1743881)
- Form: SCHEDULE 13D/A
- Filed: 2026-08-17
- Accepted by EDGAR: Aug 17, 2026, 17:30 ET
- Period: not reported
- Accession: 0001140361-26-033404
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1743881/000114036126033404/xslSCHEDULE_13D_X02/primary_doc.xml
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1743881/000114036126033404/

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1743881/000114036126033404/xslSCHEDULE_13D_X02/primary_doc.xml

Filed Aug 17, 2026.
Source: SEC EDGAR, the filing index for accession 0001140361-26-033404. Last ingested by Listed: Nov 3, 2026, 19:31 ET. No prices; not investment advice.